VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27
03 March 2017 - 12:00AM
VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of first-in-class treatments for cancer, today announced that it
will host a conference call and live audio webcast on Monday, March
27, 2017 at 8:30am Eastern Time to report fourth quarter and
full-year ended December 31, 2016 financial results.
Monday, March 27th @
8:30am Eastern Time |
Domestic: |
888-727-7622 |
International: |
913-312-0384 |
Conference ID: |
8563883 |
Webcast: |
http://edge.media-server.com/m/p/npmjtb62 |
|
Replays,
available through April 10, 2017: |
Toll Free: |
844-512-2921 |
International: |
412-317-6671 |
Conference ID: |
8563883 |
About VBL Vascular Biogenics Ltd.,
operating as VBL Therapeutics, is a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class treatments for cancer. The
Company’s lead oncology product candidate, ofranergene obadenovec
(VB-111), is a first-in-class, targeted anti-cancer gene-therapy
agent that is positioned to treat a wide range of solid tumors. It
is conveniently administered as an IV infusion once every two
months. It has been observed to be well-tolerated in >200 cancer
patients and we have observed its efficacy signals in an “all
comers” Phase 1 trial as well as in three tumor-specific Phase 2
studies. Ofranergene obadenovec is currently being studied in a
Phase 3 pivotal trial for recurrent Glioblastoma, conducted under
an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024